Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MyCelx Technologies Corporation Report Publication Announcement 2019

May 31, 2019

10837_10-k_2019-05-31_a3b7fe56-6ba2-4e95-a903-cec91a673150.html

Report Publication Announcement

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7978A

MyCelx Technologies Corporation

31 May 2019

MYCELX Technologies Corporation   

("MYCELX" or the "Company") (AIM: MYX)

31 May 2019

Mailing of 2018 Annual Report and Notice of 2019 Annual Meeting

Following the release on 13 May 2019 of the Company's Final Results for the year ended 31 December 2018, MYCELX announces that the 2018 Annual Report is being mailed today to shareholders, together with the Notice of 2019 Annual Meeting, the Form of Proxy and the Form of Direction for depository interest holders.

Copies have been placed on the Company's website at www.mycelx.com. Copies will also be available free of charge from the Company's headquarters at 2420 Meadowbrook Parkway, Duluth, Georgia, GA 30096, USA for a period of at least one month.

Annual Meeting

The Company's 2019 Annual Meeting will be held at 12 noon (BST) on Wednesday 10 July 2019 at the offices of Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London EC1Y 4AG.

For further information please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO
Tel: +1 888 306 6843
Cantor Fitzgerald Europe

Nominated Adviser and Broker

David Porter

Richard Salmond
Tel: +44 20 7894 7000
Celicourt Communications

Mark Antelme

Jimmy Lea
Tel: +44 20 7520 9266

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ACSUAVURKOAVOAR